Overview
Analgesic Effectiveness of Nefopam in Patients Undergoing Anterior Cervical Spine Surgery
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2021-05-31
2021-05-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine. It has no respiratory depression so may be useful in potential airway compromized surgery like anterior cervical discectomy and fusion (ACDF). This study aims to study the analgesic properties of nefopam after ACDF.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Mahidol UniversityTreatments:
Analgesics
Nefopam
Criteria
Inclusion Criteria:- Patients with cervical spondylosis or cervical spondylotic myelopathy undergoing
elective anterior cervical spine surgery such as ACDF or anterior cervical corpectomy
and fusion (ACCF)
- American Society of Anesthesiologists (ASA) class I-III
- Age 18-75 years old
- Body weight > 50 kg, BMI < 30 kg/m2
Exclusion Criteria:
- Convulsion or seizure
- Myocardial ischemia or infarction
- Risk of urinary retention from urethral disease or prostate disease
- Angle closure glaucoma
- Patients on monoamine oxidase inhibitor
- Psychiatric patients
- Pregnant or lactated woman
- Creatinine clearance < 30 ml/min
- Allergic to nefopam
- Patients on pregabaline or gabapentin
- Poorly controlled hypertension
- Cannot understand or do the questionnaire of Thai version of Neuropathic pain symptom
inventory (NPSI-T) score